DEPDC1 as a metabolic target regulates glycolysis in renal cell carcinoma through AKT/mTOR/HIF1α pathway

Abstract Renal cell carcinoma (RCC) is considered a “metabolic disease” characterized by elevated glycolysis in patients with advanced RCC. Tyrosine kinase inhibitor (TKI) therapy is currently an important treatment option for advanced RCC, but drug resistance may develop in some patients. Combining...

Полное описание

Библиографические подробности

Главные авторы:	Si-chen Di, Wen-jin Chen, Wei Yang, Xiang-min Zhang, Ke-qin Dong, Yi-jun Tian, Ye Sun, Cheng Qian, Jia-xin Chen, Zi-chang Liu, Zi-xuan Gong, Jian Chu, Wang Zhou, Xiu-wu Pan, Xin-gang Cui
Формат:	Artigo
Язык:	Inglês
Опубликовано:	Nature Publishing Group 2024-07-01
Серии:	Cell Death and Disease
Online-ссылка:	https://doi.org/10.1038/s41419-024-06913-1
Метки:	Добавить метку Нет меток, Требуется 1-ая метка записи!